Zydus Lifesciences Q1 FY27: Growth surges as margins reset amid specialty bets

Consolidated revenues from operations were INR 80,170 million (INR 8,017 crore), up 22.0 percent year-on-year.

EBITDA was INR 19,294 million (INR 1,929.4 crore) with a 24.1 percent margin. Reported net profit was INR 9,398 million (INR 939.8 crore), down 35.9 percent year-on-year.

Management guided for around INR 1,500 to 1,600 crore of capex for FY27.

Management reiterated strong double-digit revenue growth for FY27 and maintained EBITDA margin guidance of 24 percent plus, noting Saroglitazar related spend rises in the second half.

India formulations INR 1,815.8 crore, North America formulations INR 3,097.9 crore, International markets INR 973.5 crore, and Consumer wellness INR 1,429.2 crore.

The company launched NUFYMCO (Ranibizumab) injection as its first US biosimilar and completed the acquisition of Assertio Holdings; management said Assertio will start contributing from the next quarter.

Management stated the USFDA granted priority review to the NDA for Saroglitazar Magnesium for Primary Biliary Cholangitis, with an FY28 (April) launch being built and peak sales guidance of 200 to 300 million USD conservatively and 400 million USD plus on an optimistic view.